05 Jun '17, 4pm

MDS Clinical Trial:

This is a phase 1/2 study to evaluate the combination of vadastuximab talirine (SGN-CD33A) and azacitidine in subjects with previously untreated International Prognostic Scoring System (IPSS) Intermediate-2 or high risk myelodysplastic syndrome (MDS). Primary objectives include determining the recommended dose of vadastuximab talirine (SGN-CD33A) in combination with azacitidine (in the open-label Phase 1 portion), and to compare the overall response rate between treatment arms (in the randomized, double-blinded,

Full article: http://www.aamds.org/treatments/clinical-trials/study-vad...

Tweets

@Roxannensy

mdscollections.com 08 Jun '17, 3pm

- V neckline - Sleeveless dress - Adjustable shoulder straps - Concealed back zip - Back slit - Stretchable throughout - M...

#ThankfulThursday !! #EmmaStrong Her story is h...

aamds.org 15 Jun '17, 6pm

In January 2016, my 9 year-old daughter Emma turned yellow. After seeing her regular doctor, we were sent straight to the ...